AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$0.97
0.03 (3.56%)
▲
5d:
-5.85%
30d:
-35.35%
90d:
-22.42%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
10 traders called AKBA this week
83% bullish • 2 bearish
83% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AKBA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AKBA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $0.97, which is considered oversold relative to its 30-day fair value range of $0.98 to $1.35. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.9) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.88, while resistance sits at $1.08. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: AKBA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.20 (+348.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AKBA is in a downtrend. Immediate support is located at $0.88, while resistance sits at $1.08. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: AKBA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.20 (+348.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.98 -
$1.35
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 348.5% below Wall St target ($4.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.98 -
$1.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.88
Resistance Level
$1.08
Current Trend
Downtrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.93
Wall Street Target
$4.20
(+348.5%)
Revenue Growth (YoY)
-6.6%
Profit Margin
-8.8%
PE vs Historical
-4.9 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: June 03, 2026 4:40 PM ET
Data refreshes hourly during market hours. Next update: 5:40 PM
Data refreshes hourly during market hours. Next update: 5:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Richard C Malabre
SELL
49524 shares
2026-02-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
